Name:
BZ_ 2022_Q2_ITZ_Labcorp_biological matrices_video
Description:
BZ_ 2022_Q2_ITZ_Labcorp_biological matrices_video
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/b6304295-7dc4-47ee-9b9c-b1082afc75b6/videoscrubberimages/Scrubber_6.jpg
Duration:
T00H01M32S
Embed URL:
https://stream.cadmore.media/player/b6304295-7dc4-47ee-9b9c-b1082afc75b6
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/b6304295-7dc4-47ee-9b9c-b1082afc75b6/ITZ-Labcorp- biological matrices-video.mp4?sv=2019-02-02&sr=c&sig=Oeqw7nGvvEWmei%2FF4Zkv6xcdTcm3pPXumMUWTZNr1ss%3D&st=2024-11-25T13%3A14%3A58Z&se=2024-11-25T15%3A19%3A58Z&sp=r
Upload Date:
2022-07-07T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
[MUSIC PLAYING]
AMY WHITE: A biological matrix is the material that occupies the vacant spaces within or between cells and is integral for supporting pharmacokinetic, immunogenicity and biomarker assays during tissue engineering applications and drug analysis within the pharmaceutical and biotechnology industries.
AMY WHITE: In the last two years, the COVID-19 pandemic has strained the biological matrix supply chain. With an upsurge in demand driven by numerous COVID-19 therapeutic and vaccine development programs to combat the pandemic, along with logistical challenges, sourcing and transporting matrices, has led to increased lead times for multiple matrices.
AMY WHITE: Biological matrix shortage can potentially cause significant delays in drug development programs across the pharmaceutical and biotechnology industries. Regulatory authorities do permit the utilization of a surrogate matrix in bioanalytical methods in instances where matrices are rare or difficult to obtain, if the surrogate is appropriately selected and scientifically justified.
AMY WHITE: Learn how Labcorp Bioanalytical Services (MA,USA) are actively implementing several mitigation strategies to help alleviate the current strain on the matrix supply chain, and better prepare for any future unexpected strains. [MUSIC PLAYING]